CEP-33779: A New Treatment for Rheumatoid Arthritis
Author Information
Author(s): Kristine L Stump, Lily D Lu, Pawel Dobrzanski, Cynthia Serdikoff, Diane E Gingrich, Ben J Dugan, Thelma S Angeles, Mark S Albom, Mark A Ator, Bruce D Dorsey, Bruce A Ruggeri, Matthew M Seavey
Primary Institution: Cephalon, Inc.
Hypothesis
Can CEP-33779, a selective JAK2 inhibitor, effectively reduce symptoms of rheumatoid arthritis in mouse models?
Conclusion
CEP-33779 significantly reduces inflammation and disease symptoms in mouse models of rheumatoid arthritis.
Supporting Evidence
- CEP-33779 reduced mean paw edema and clinical scores in both CIA and CAIA models.
- Histological analysis showed reduced matrix erosion and inflammation in treated mice.
- Treatment with CEP-33779 led to decreased levels of proinflammatory cytokines.
Takeaway
Researchers tested a new medicine called CEP-33779 on mice with arthritis, and it helped make their swollen paws feel better.
Methodology
Mice with arthritis were treated with CEP-33779 at various doses, and their paw swelling and cytokine levels were measured.
Limitations
The study was conducted only in mouse models, which may not fully represent human responses.
Participant Demographics
Female DBA/1 and Balb/c mice, aged 6 to 8 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website